Physician profile
Ace E Alvarez
NPI 1083966873
$22,147.15
in general payments reported to CMS, 2019-2025
40 companies · $4,938 in 2025
The $4,938 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,025 · 2022: $4,018 · 2023: $4,265 · 2024: $4,901 · 2025: $4,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $81.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,023.13 |
| Education | $81.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,856.69 | 2021-2025 | Airsupra, Farxiga, Lokelma |
| Novo Nordisk INC | $2,705.48 | 2021-2025 | Ozempic, Wegovy |
| Amgen INC. | $1,762.40 | 2021-2025 | Repatha, Repatha, Otezla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,461.49 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,287.55 | 2021-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $1,174.04 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,102.71 | 2021-2025 | |
| Pfizer INC. | $1,029.25 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $886.57 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $762.02 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $754.06 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $745.40 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $710.88 | 2021-2025 | Verquvo, Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $591.23 | 2024-2025 | Voquezna |
| Abbvie INC. | $530.82 | 2021-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $502.11 | 2023-2025 | Dexcom G6 Transmitter |
| Scpharmaceuticals INC. | $420.16 | 2023-2025 | |
| Abbott Laboratories | $411.31 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Astellas Pharma US INC | $408.79 | 2021-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $370.71 | 2021-2025 | Camzyos, Eliquis |
| Axsome Therapeutics, INC. | $262.22 | 2023 | Auvelity |
| Esperion Therapeutics, INC. | $235.03 | 2021 | |
| Zynex Medical, INC. | $232.78 | 2025 | Nexwave |
| Heartflow, INC. | $160.38 | 2025 | |
| Insulet Corporation | $150.00 | 2025 | Omnipod |
| Lexicon Pharmaceuticals, INC. | $142.89 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $128.88 | 2021-2024 | Zepbound |
| Xeris Pharmaceuticals, INC. | $59.91 | 2023 | Gvoke Hypopen |
| Exeltis, USA INC. | $54.19 | 2023 | Slynd |
| Edwards Lifesciences Corporation | $39.79 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sumitomo Pharma America, INC. | $29.34 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.00 | 2022 | |
| Amarin Pharma, INC. | $22.49 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.49 | 2025 | Uptravi, Opsumit |
| Genzyme Corporation | $21.18 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.42 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.01 | 2021 | |
| Baxter Healthcare | $19.31 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Vivus LLC | $17.43 | 2024 | Qsymia |
| Teva Pharmaceuticals USA, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ace Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.